| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8233463 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 7 Pages |
Abstract
The addition of bevacizumab to neoadjuvant chemoradiation resulted in encouraging pathologic complete response without an increase in acute toxicity. The impact of bevacizumab on perineal wound and anastamotic healing due to concurrent bevacizumab requires further study.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Christopher H. M.D., Cathy M.D., Barry W. M.D., Prajnan M.D., John M. M.D., George J. M.D., Robert A. M.D., Sunil M.D., Stanley M.D., Nora A. M.D., Dipen M. M.D., Lee M. M.D., Miguel A. M.D.,